Amyloid beta protein-induced zinc sequestration leads to synaptic loss via dysregulation of the ProSAP2/Shank3 scaffold

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Grabrucker, Andreas M ^a,b   Schmeisser, Michael J ^a   Udvardi, Patrick T ^a   Arons, Magali ^b   Schoen, Michael ^a   Woodling, Nathaniel S ^b   Andreasson, Katrin I ^b   Hof, Patrick R ^c   Buxbaum, Joseph D ^c   Garner, Craig C ^b   Boeckers, Tobias M ^a  

^a UNIVERSITY OF ULM   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid; Hippocampus; Oligomers; ProSAP2; PSD; Shank1; Shank3; synapse; Zn 2+

Indexed keywords

AMYLOID BETA PROTEIN; PROTEIN PROSAP2; PROTEIN SHANK3; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; ZINC ION;

AGED; ANIMAL TISSUE; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DENDRITE; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; POSTSYNAPTIC DENSITY; PROTEIN ASSEMBLY; RAT;

MUS; RATTUS;

EID: 80053172434     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-65     Document Type: Article

References (60)

1. Synaptic loss in Alzheimer's disease and other dementias. Hamos JE, DeGennaro LJ, Drachman D, Neurology 1989 39 3 355 361 2927643 (Pubitemid 19094725)
2. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R, Ann Neurol 1991 30 572 580 10.1002/ana.410300410 1789684
3. Structural correlates of cognition in dementia: quantification and assessment of synapse change. DeKosky ST, Scheff SW, Styren SD, Neurodegeneration 1996 5 417 421 10.1006/neur.1996.0056 9117556 (Pubitemid 27077903)
4. Amyloid protein precursor and the pathogenesis of Alzheimer's disease. Selkoe D, Cell 1989 58 611 612 10.1016/0092-8674(89)90093-7 2504495 (Pubitemid 19210954)
5. Physiological production of the -amyloid protein and the mechanisms of Alzheimer's disease. Selkoe D, Trends Neurosci 1993 16 403 409 10.1016/0166-2236(93)90008-A 7504355 (Pubitemid 23283401)
6. Role of the beta-amyloid protein in Alzheimer's disease. Sisodia SS, Price DL, FASEB J 1995 9 366 370 7896005
7. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E, FEBS J 2010 277 3051 3067 10.1111/j.1742-4658.2010.07719.x 20573181
8. Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synaptopathies. Grabrucker AM, Schmeisser MJ, Schoen M, Boeckers TM, Trends Cell Biol 2011
9. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, Nygren G, Rastam M, Gillberg IC, Anckarsäter H, Sponheim E, Goubran-Botros H, Delorme R, Chabane N, Mouren-Simeoni MC, de Mas P, Bieth E, Rogé B, Héron D, Burglen L, Gillberg C, Leboyer M, Bourgeron T, Nat Genet 2007 39 1 25 27 10.1038/ng1933 17173049 (Pubitemid 46026497)
10. Contribution of SHANK3 mutations to autism spectrum disorder. Moessner R, Marshall CR, Sutcliffe JS, Skaug J, Pinto D, Vincent J, Zwaigenbaum L, Fernandez B, Roberts W, Szatmari P, Scherer SW, Am J Hum Genet 2007 81 6 1289 1297 10.1086/522590 17999366 (Pubitemid 350211458)
11. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Gauthier J, Champagne N, Lafrenière RG, Xiong L, Spiegelman D, Brustein E, Lapointe M, Peng H, Côté M, Noreau A, Hamdan FF, Addington AM, Rapoport JL, Delisi LE, Krebs MO, Joober R, Fathalli F, Mouaffak F, Haghighi AP, Néri C, Dubé MP, Samuels ME, Marineau C, Stone EA, Awadalla P, Barker PA, Carbonetto S, Drapeau P, Rouleau GA, Proc Natl Acad Sci USA 2010 107 17 7863 7868 10.1073/pnas.0906232107 20385823
12. Disruption of glutamate receptors at Shank-postsynaptic platform in Alzheimer's disease. Gong Y, Lippa CF, Zhu J, Lin Q, Rosso AL, Brain research 2009 1292 191 198 19635471
13. Disassembly of shank and homer synaptic clusters is driven by soluble beta-amyloid(1-40) through divergent NMDAR-dependent signalling pathways. Roselli F, Hutzler P, Wegerich Y, Livrea P, Almeida OF, PLoS one 2009 4 6 6011 10.1371/journal.pone.0006011
14. Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, Morabito M, Almeida OF, J Neurosci 2005 25 48 11061 11070 10.1523/JNEUROSCI.3034-05.2005 16319306 (Pubitemid 43089551)
15. CDK5 is essential for soluble amyloid -induced degradation of GKAP and remodeling of the synaptic actin cytoskeleton. Roselli F, Livrea P, Almeida OF, PLoS one 2011 6 7 23097 10.1371/journal.pone.0023097
16. An architectural framework that may lie at the core of the postsynaptic density. Baron MK, Boeckers TM, Vaida B, Faham S, Gingery M, Sawaya MR, Salyer D, Gundelfinger ED, Bowie JU, Science 2006 311 5760 531 535 10.1126/science. 1118995 16439662 (Pubitemid 43157732)
17. Concerted action of zinc and ProSAP/Shank in synaptogenesis and synapse maturation. Grabrucker AM, Knight MJ, Proepper C, Bockmann J, Joubert M, Rowan M, Nienhaus GU, Garner CC, Bowie JU, Kreutz MR, Gundelfinger ED, Boeckers TM, EMBO J 2011 30 3 569 581 10.1038/emboj.2010.336 21217644
18. A role for zinc in postsynaptic density asSAMbly and plasticity? Gundelfinger ED, Boeckers TM, Baron MK, Bowie JU, Trends Biochem Sci 2006 31 7 366 373 10.1016/j.tibs.2006.05.007 16793273 (Pubitemid 44056319)
19. Synaptically released zinc: physiological functions and pathological effects. Frederickson CJ, Bush AI, Biometals 2001 14 3-4 353 366 11831465 (Pubitemid 34066638)
20. Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. Lee JY, Mook-Jung I, Koh JY, J Neurosci 1999 19 11 C10 10341271
21. Copper, iron and zinc in Alzheimer's disease senile plaques. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR, J Neurol Sci 1998 158 1 47 52 10.1016/S0022-510X(98)00092-6 9667777 (Pubitemid 28277534)
22. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G, Frederickson CJ, Brain Res 2000 852 2 274 278 10.1016/S0006-8993(99)02096-X 10678753 (Pubitemid 30035163)
23. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI, J Neurochem 2000 75 3 1219 1233 10936205 (Pubitemid 30660512)
24. Rapid induction of Alzheimer Abeta amyloid formation by zinc. Bush AI, Pettingell WH, Multhaup G, d. Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE, Science 1994 265 5177 1464 1467 10.1126/science.8073293 8073293 (Pubitemid 24306803)
25. Zinc ions promote Alzheimer Abeta aggregation via population shift of polymorphic states. Miller Y, Ma B, Nussinov R, Proc Natl Acad Sci USA 2010 107 21 9490 9495 10.1073/pnas.0913114107 20448202
26. Proline-rich synapse-associated protein-1/cortactin binding protein 1 (ProSAP1/CortBP1) is a PDZ-domain protein highly enriched in the postsynaptic density. Boeckers TM, Kreutz MR, Winter C, Zuschratter W, Smalla KH, Sanmarti-Vila L, Wex H, Langnaese K, Bockmann J, Garner CC, Gundelfinger ED, J Neurosci 1999 19 15 6506 6518 10414979 (Pubitemid 29347450)
27. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Sala C, Pich V, Wilson NR, Passafaro M, Liu G, Sheng M, Neuron 2001 31 1 115 130 10.1016/S0896-6273(01)00339-7 11498055 (Pubitemid 32757093)
28. Measurement of zinc in hepatocytes by using a fluorescent probe, zinquin: relationship to metallothionein and intracellular zinc. Coyle P, Zalewski PD, Philcox JC, Forbes IJ, Ward AD, Lincoln SF, Mahadevan I, Rofe AM, Biochem J 1994 303 3 781 786 7980447 (Pubitemid 24326011)
29. Examining the zinc binding site of the amyloid-beta peptide. Yang DS, McLaurin J, Qin K, Westaway D, Fraser PE, Eur J Biochem 2000 267 22 6692 6698 11054124
30. Zinc binding to amyloid-beta: isothermal titration calorimetry and Zn competition experiments with Zn sensors. Talmard C, Bouzan A, Faller P, Biochemistry 2007 46 47 13658 13666 10.1021/bi701355j 17983245 (Pubitemid 350209961)
31. High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide. Danielsson J, Pierattelli R, Banci L, Gräslund A, FEBS J 2007 274 1 46 59 10.1111/j.1742-4658.2006.05563.x 17222176 (Pubitemid 44952897)
32. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL, J Neurosci 2007 27 796 807 10.1523/JNEUROSCI.3501-06.2007 17251419 (Pubitemid 46174498)
33. Abeta(1-40) forms five distinct amyloid structures whose beta-sheet contents and fibril stabilities are correlated. Kodali R, Williams AD, Chemuru S, Wetzel R, J Mol Biol 2010 401 3 503 517 10.1016/j.jmb.2010.06.023 20600131
34. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Selkoe DJ, Behav Brain Res 2008 192 106 113 10.1016/j.bbr.2008.02. 016 18359102
35. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL, Proc Natl Acad Sci USA 1998 95 6448 6453 10.1073/pnas.95.11.6448 9600986 (Pubitemid 28249033)
36. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Klein WL, Krafft GA, Finch CE, Trends Neurosci 2001 24 219 224 10.1016/S0166-2236(00)01749-5 11250006 (Pubitemid 32204378)
37. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Walsh DM, Selkoe DJ, Protein Pept Lett 2004 11 213 228 10.2174/0929866043407174 15182223 (Pubitemid 38689025)
38. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ, J Neurosci 2008 28 4231 4237 10.1523/JNEUROSCI.5161-07.2008 18417702
39. Modulation of Abeta adhesiveness and secretase site cleavage by zinc. Bush AI, Pettingell WH, Paradis MD, Tanzi RE, J Biol Chem 1994 269 16 12152 12158 8163520
40. Selection of novel structural zinc sites from a random peptide library. Matsubara T, Hiura Y, Kawahito O, Yasuzawa M, Kawashiro K, FEBS Lett 2003 555 2 317 321 10.1016/S0014-5793(03)01266-3 14644435 (Pubitemid 37486048)
41. Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease? Adlard PA, Parncutt JM, Finkelstein DI, Bush AI, J Neurosci 2010 30 5 1631 1636 10.1523/JNEUROSCI.5255- 09.2010 20130173
42. Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Cole TB, Wenzel HJ, Kafer KE, Schwartzkroin PA, Palmiter RD, Proc Natl Acad Sci USA 1999 96 4 1716 1721 10.1073/pnas.96.4.1716 9990090 (Pubitemid 29098517)
43. A Role for Synaptic Zinc in Activity-Dependent A Oligomer Formation and Accumulation at Excitatory Synapses. Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J, J Neurosci 2009 29 13 4004 4015 10.1523/JNEUROSCI.5980-08.2009 19339596
44. Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Gylys KH, Fein JA, Yang F, Wiley DJ, Miller CA, Cole GM, Am J Pathol 2004 165 1809 1817 10.1016/S0002-9440(10)63436-0 15509549 (Pubitemid 39435178)
45. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL, Proc Natl Acad Sci USA 2009 106 4012 4017 10.1073/pnas.0811698106 19228947
46. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ, J Neuropathol Exp Neurol 1997 56 8 933 944 10.1097/00005072-199708000-00011 9258263 (Pubitemid 27329114)
47. Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurodegenerative disorders with dementia. Zhan SS, Beyreuther K, Schmitt HP, Dementia 1993 4 2 66 74 8358515 (Pubitemid 23125353)
48. Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). Viola KL, Velasco PT, Klein WL, J Nutr Health Aging 2008 12 51 57 10.1007/BF02982587
49. Mechanism of neuronal versus endothelial cell uptake of Alzheimer's disease amyloid beta protein. Kandimalla KK, Scott OG, Fulzele S, Davidson MW, Poduslo JF, PLoS One 2009 4 2 4627 10.1371/journal.pone.0004627 19247480
50. Mechanisms of amyloid-Beta Peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins. Lai AY, McLaurin J, Int J Alzheimers Dis 2010 2011 548380 21197446
51. Intracellular amyloid-beta in Alzheimer's disease. LaFerla FM, Green KN, Oddo S, Nat Rev Neurosci 2007 8 7 499 509 10.1038/nrn2168 17551515 (Pubitemid 46985362)
52. Zinc dyshomeostasis, ageing and neurodegeneration: implications of A2M and inflammatory gene polymorphisms. Mocchegiani E, Malavolta M, J Alzheimers Dis 2007 12 1 101 109 17851198 (Pubitemid 47396309)
53. Metallothionein-I and -III expression in animal models of Alzheimer disease. Carrasco J, Adlard P, Cotman C, Quintana A, Penkowa M, Xu F, Van Nostrand WE, Hidalgo J, Neuroscience 2006 143 4 911 922 10.1016/j.neuroscience. 2006.08.054 17027170 (Pubitemid 44834444)
54. Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain. Lyubartseva G, Smith JL, Markesbery WR, Lovell MA, Brain Pathol 2010 20 2 343 350 10.1111/j.1750-3639.2009.00283.x 19371353
55. Elevation of zinc transporter ZnT3 protein in the cerebellar cortex of the AbetaPP/PS1 transgenic mouse. Zheng W, Wang T, Yu D, Feng WY, Nie YX, Stoltenberg M, Danscher G, Wang ZY, J Alzheimers Dis 2010 20 1 323 331 20164588
56. Serum zinc is decreased in Alzheimer's disease and serum arsenic correlates positively with cognitive ability. Baum L, Chan IH, Cheung SK, Goggins WB, Mok V, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Zee BC, Cheng W, Chan MH, Szeto S, Lui V, Tsoh J, Bush AI, Lam CW, Kwok T, Biometals 2010 23 1 173 179 10.1007/s10534-009-9277-5 19911117
57. Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunction. Corona C, Masciopinto F, Silvestri E, Del Viscovo A, Lattanzio R, Sorda RL, Ciavardelli D, Goglia F, Piantelli M, Canzoniero LM, Sensi SL, Cell Death and Disease 2010 1 1 8 10.1038/cddis.2009.2
58. Presenilins promote the cellular uptake of copper and zinc and maintain Cu-chaperone of sod1-dependent Cu/Zn superoxide dismutase activity. Greenough MA, Volitakis I, Li QX, Laughton K, Evin G, Ho M, Dalziel AH, Camakaris J, Bush AI, J Biol Chem 2011
59. Ibuprofen and lipoic acid diamide as co-drug with neuroprotective activity: pharmacological properties and effects in beta-amyloid (1-40) infused Alzheimer's disease rat model. Di Stefano A, Sozio P, Cerasa LS, Iannitelli A, Cataldi A, Zara S, Giorgioni G, Nasuti C, Int J Immunopathol Pharmacol 2010 2 589 599
60. Synaptic crosstalk betweeen N-methyl-D-aspartate receptors and LAPSER1-beta-catenin at excitatory synapses. Schmeisser MJ, Grabrucker AM, Bockmann J, Boeckers TM, J Biol Chem 2009 284 42 29146 29157 10.1074/jbc.M109.020628 19703901